Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, linking its hereditary angioedema (HAE) prospect to an 81% reduction in monthly attacks in a phase 2 trial.